MAPT and Alzheimer disease: Unlike APP transgenic mice,21,25App KI mice seem to develop milder cognitive changes.16-19,23 As suggested,15,20App KI mice may model pre-clinical stages of AD, characterized by progressive amyloidosis and gliosis without prominent cognitive deterioration, tau pathology, or neurodegeneration.